IGC
IGC Pharma, Inc.
IGC has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over IGC overall, supported by stronger fundamentals and stronger modeled upside.
IGC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
IGC's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
IGC PE Valuation
IGC has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
IGC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect IGC's revenue to grow, with its earnings and profitability holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
IGC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.08 | $0.00 |
| Q2 2026 | -$0.08 | $0.00 |
| Q1 2026 | -$0.07 | +$0.02 |
| Q4 2025 | -$0.06 | +$0.06 |
| Q3 2025 | -$0.08 | +$0.11 |
| Q2 2025 | -$0.08 | +$0.13 |
| Q1 2025 | -$0.09 | +$0.13 |
| Q4 2024 | -$0.12 | +$0.13 |
IGC is still losing money, but far less than before: $0.08 per share over the past year, against $0.32 at its worst in mid-2022.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over IGC on earnings quality, reporting a profit while its opponent remains loss making.
IGC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $328K | +72% |
| Q2 2026 | $265K | -19% |
| Q1 2026 | $317K | -3.9% |
| Q4 2025 | $350K | +36% |
| Q3 2025 | $191K | -54% |
| Q2 2025 | $328K | +21% |
| Q1 2025 | $330K | +12% |
| Q4 2024 | $257K | +26% |
IGC's revenue is recovering but still below its 2020 peak: $328,000 last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -589% | +929 points |
| Q2 2026 | -1051% | -470 points |
| Q1 2026 | -775% | -348 points |
| Q4 2025 | -840% | -110 points |
| Q3 2025 | -1518% | -1091 points |
| Q2 2025 | -581% | +300 points |
| Q1 2025 | -428% | +308 points |
| Q4 2024 | -731% | +739 points |
IGC's operating margin was −589% last quarter, up 929 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over IGC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over IGC on profitability, with a higher operating margin.
IGC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.4M | +$702K |
| Q2 2026 | -$1.4M | +$60K |
| Q1 2026 | -$1.2M | -$476K |
| Q4 2025 | -$1.2M | +$109K |
| Q3 2025 | -$2.1M | -$1.1M |
| Q2 2025 | -$1.4M | +$375K |
| Q4 2024 | -$1.3M | +$243K |
| Q3 2024 | -$1M | +$593K |
IGC has burned cash in almost every quarter: −$5M over the past year, against −$6M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over IGC on cash generation, producing positive trailing cash flow while its opponent burns cash.
IGC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.1% | +9.2M shares |
| 1 year | +21% | +19M shares |
| 3 years | +106% | +56.4M shares |
| 5 years | +129% | +61.6M shares |
IGC has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
IGC Net Leverage
IGC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
IGC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.4 | Neutral |
| Stochastic | 42.1 | Neutral |
IGC's weekly RSI is 30 (neutral) and its Stochastic is 42 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
IGC PE vs Healthcare Sector
IGC has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
IGC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.24 | 25% below |
| 20 week MA | $0.26 | 31% below |
| 50 week MA | $0.28 | 36% below |
| 100 week MA | $0.31 | 42% below |
| 200 week MA | $0.34 | 47% below |
IGC is in a downtrend: it's below all five of its weekly moving averages, and 47% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over IGC on trend strength, trading above more of its moving averages.
IGC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.61 | $1.75 | +187% |
| 2021 | $1.75 | $1.15 | -34% |
| 2022 | $1.15 | $0.34 | -70% |
| 2023 | $0.34 | $0.28 | -18% |
| 2024 | $0.28 | $0.37 | +32% |
| 2025 | $0.37 | $0.30 | -19% |
| 2026 YTD | $0.30 | $0.18 | -40% |
IGC's yearly returns have swung widely, from +187% in 2020 to −70% in 2022. It's down 40% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over IGC on returns for 2026, with the stronger performance.